Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

PURPOSE: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: In this multicenter, two-stage, phase...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Reid, Alison H.M., Attard, Gerhardt, Danila, Daniel C., Oommen, Nikhil Babu, Olmos, David, Fong, Peter C., Molife, L. Rhoda, Hunt, Joanne, Messiou, Christina, Parker, Christopher, Dearnaley, David, Swennenhuis, Joost F., Terstappen, Leon W.M.M., Lee, Gloria, Kheoh, Thian, Molina, Arturo, Ryan, Charles J., Small, Eric, Scher, Howard I., de Bono, Johann S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849770/
https://ncbi.nlm.nih.gov/pubmed/20159823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.6819
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items